Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: A report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)

Blood

Volumn 116, Issue 19, 2010, Pages 3735-3742

  Thepot, Sylvain ^a,b   Itzykson, Raphael ^a   Seegers, Valerie ^c   Raffoux, Emmanuel ^c   Quesnel, Bruno ^d   Chait, Yasmine ^e   Sorin, Lucile ^f   Dreyfus, Francois ^g   Cluzeau, Thomas ^h   Delaunay, Jacques ⁱ   Sanhes, Laurence ^j   Eclache, Virginie ^k   Dartigeas, Caroline ^l   Turlure, Pascal ^m   Harel, Stephanie ⁿ   Salanoubat, Celia ^o   Kiladjian, Jean Jacques ^c   Fenaux, Pierre ^a,b   Adès, Lionel ^a,b  

^a AVICENNE HOSPITAL   (France)

^b Institut Gustave Roussy   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e Groupe Hospitalier Intercommunal   (France)

^f CHU PURPAN   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁱ UNIVERSITÉ DE NANTES   (France)

^j Centre Hospitalier de Perpignan   (France)

^k UNIVERSITÉ PARIS 13   (France)

^l UNIVERSITÉ DE TOURS   (France)

^m UNIVERSITY OF LIMOGES   (France)

ⁿ HÔPITAL NECKER ENFANTS MALADES   (France)

^o Service d'Hematologie   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ARABINOSIDE; AZACITIDINE; HYDROXYUREA; IMATINIB; PIPOBROMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; THROMBOCYTHEMIA; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

EID: 78149453788     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-274811     Document Type: Article

References (35)

1. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycy-themia vera associated with chlorambucil therapy. N Engl J Med. 1981;304(8):441-447.
2. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105(7):2664-2670. (Pubitemid 40446255)
3. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32(4 Pt 2):417-421.
4. Kiladjian J-J, Chevret S, Abgrall J-F, Chait Y, Briere J. Risk stratification for survival and clonal progression in essential thrombocythemia (ET): result of a prospective study of 108 patients with very long term follow up [abstract]. Blood. 2008;112(11):Abstract 1747.
5. Passamonti F, Rumi E, Arcaini L, et al. Leukemic transformation of polycythemia vera: a single center study of 23 patients. Cancer. 2005;104(5):1032-1036. (Pubitemid 41170231)
6. Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009;27(33):5587-5593.
7. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009;113(6):1315-1325.
8. Wang JC, Chen W, Nallusamy S, Chen C, Novetsky AD. Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Br J Haematol. 2002;116(3):582-586. (Pubitemid 34178657)
9. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429-2440. (Pubitemid 34525728)
10. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
11. Quintas-Cardama A, Tong W, Kantarjian H, et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/ polycythemia vera myelofibrosis. Leukemia. 2008;22(5):965-970. (Pubitemid 351689878)
12. Mesa RA, Verstovsek S, Rivera C, et al. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia. 2009;23(1):180-182.
13. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
14. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-199.
15. Laszlo J. Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol. 1975;12(4):409-432.
16. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12(4):339-351.
17. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.
18. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425.
19. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649.
20. Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009;27(33):5587-5593.
21. Kaplan E, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assos. 1958;53:457.
22. Cox D. Regression models and life-tables (with discussion). J R Stat Soc B. 1972;34:487.
23. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794-1803.
24. Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol. 1991;85(3):124-127.
25. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973-977. (Pubitemid 40170863)
26. Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008;112(5):1628-1637.
27. Kantarjian HM, O'Brien SM, Keating M, et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia. 1997;11(10):1617-1620. (Pubitemid 27458597)
28. Sacchi S, Kantarjian HM, O'Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86(12):2632-2641. (Pubitemid 30004667)
29. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6(2):107-116.
30. Yu L, Liu C, Vandeusen J, et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet. 2005;37(3):265-274. (Pubitemid 41716253)
31. Capello D, Deambrogi C, Rossi D, et al. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol. 2008;141(4):504-511. (Pubitemid 351550557)
32. Jost E, do ON, Dahl E, et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia. 2007;21(3):505-510. (Pubitemid 46306562)
33. Fourouclas N, Li J, Gilby DC, et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica. 2008;93(11):1635-1644.
34. Bogani C, Ponziani V, Guglielmelli P, et al. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells. 2008;26(8):1920-1930.
35. Dawson MA, Bannister AJ, Gottgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009;461(7265):819-822.